DBV Technologies S.A. DBVT
11.29 USD +0.24 (+2.16%)
Nov 10, 2026, 1:08 PM EST
10.95 Day range 11.42
8.63 52-week range 26.19
- YTD
- -41.11%
- 1 year
- -16.87%
News
seekingalpha.com DBV Technologies: Down 55% Since April, Yet My $42 Fair Value Still Holds DBV Technologies is rated Speculative Strong Buy with a $42 per ADS fair value, despite recent sector- and company-specific share price declines. My revised DCF incorporates higher discount rates,…
benzinga.com Guggenheim Maintains Buy on DBV Technologies, Lowers Price Target to $46 Guggenheim analyst Yatin Suneja maintains DBV Technologies (NASDAQ:DBVT) with a Buy and lowers the price target from $51 to $46.
benzinga.com Citizens Maintains Market Outperform on DBV Technologies, Lowers Price Target to $47 Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and lowers the price target from $55 to $47.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com ServiceNow Posts Downbeat Q3 Earnings, Joins Sprouts Farmers Market, Alphabet And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as ServiceNow plunged 18.5% after missing earnings estimates, while Fortinet, Sprouts and Alphabet also fell.
benzinga.com DBV Technologies Q3 2026 Earnings Call Transcript DBV Technologies (NASDAQ:DBVT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com DBV Technologies Q3 EPS $(0.14) Beats $(0.24) Estimate, Sales $1.600M Beat $820.000K Estimate DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.24) by 41.67 percent. This is a 41.67 percent increase over losses of…
benzinga.com Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 YearsThe BLA is supported by the results from the successful…
benzinga.com DBV Technologies Q2 EPS $(0.12) Misses $(0.10) Estimate, Sales $700.000K Miss $1.391M Estimate DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 61.29 percent increase over losses of…- benzinga.com Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55 Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $47 to $55.
benzinga.com DBV Technologies To Present New Data From VITESSE Study And Preview Recently Initiated THRIVE Study At EAACI Congress 2026 In the Phase 3 VITESSE study, VIASKIN® Peanut Patch demonstrated statistically significant efficacy vs. placebo in the subgroups of children with peanut allergy who also had another common atopic…
benzinga.com DBV Technologies Starts Infant Study of Peanut Allergy Patch DBV Technologies (TRQX:DBVp), a late-stage biopharmaceutical company, today announced that the first participant has been screened in the THRIVE Phase 2 clinical study evaluating the efficacy and…
benzinga.com Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintains $51 price target.
benzinga.com Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55 Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $47 to $55.- benzinga.com DBV Technologies Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $900.000K Miss $1.268M Estimate DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 57.69 percent increase over losses of…
benzinga.com DBV Technologies Sets Stage For 'Swift' Success As Breakthrough Peanut Patch Nears FDA Submission DBV Tech (DBVT) maintains progress with BLA submission for VIASKIN peanut patch in children. Analyst maintains Buy rating with $51 target.
benzinga.com Alphabet To Rally Over 41%? Here Are 10 Top Analyst Forecasts For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, visit our analyst ratings page.- benzinga.com Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $47 Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $45 to $47.
- benzinga.com Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target Guggenheim analyst Yatin Suneja reiterates DBV Technologies (NASDAQ:DBVT) with a Buy and maintains $51 price target.
- benzinga.com DBV Technologies Q4 EPS $(0.23) Beats $(0.63) Estimate, Sales $645.000K Miss $655.000K Estimate DBV Technologies (NASDAQ:DBVT) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.63) by 63.49 percent. This is a 4.55 percent decrease over losses of…
benzinga.com Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings and sales. Other stocks also down in pre-market.
benzinga.com Hesai Group, BitFuFu And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Dow futures down 0.2%. Hesai Group -ADR shares drop 6.6% after reporting lower quarterly earnings and sales. Other stocks also down in pre-market.- benzinga.com Reported Saturday, DBV Technologies Reports Broad Desensitization In Phase 3 VITESSE Study, 60.1% Increase Two Doses With VIASKIN Peanut Patch Vs 23.4% Placebo DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual MeetingApproximately 83% of children treated with the VIASKIN® Peanut Patch increased their…
- benzinga.com DBV Technologies To Present VITESSE Phase 3 Study Of VIASKIN Peanut Patch Data At AAAAI 2026 Annual Meeting DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Worthington Steel, Immunitybio, Riot Platforms, Micron Technology And Other Big Stocks Moving Higher On Friday 
benzinga.com How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.
benzinga.com The Insider Report: A Tape Fitting for the Holiday 
benzinga.com Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Honeywell, Intuitive Machines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Clearwater Analytics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket 
benzinga.com Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com Why MillerKnoll Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Crude Oil Rises Over 1%; General Mills Earnings Top Views - benzinga.com HC Wainwright & Co. Maintains Buy on DBV Technologies, Raises Price Target to $40 HC Wainwright & Co. analyst Andrew S. Fein maintains DBV Technologies (NASDAQ:DBVT) with a Buy and raises the price target from $35 to $40.
benzinga.com Toro, DBV Technologies, Udemy, ABM Industries And Other Big Stocks Moving Higher On Wednesday - benzinga.com Cantor Fitzgerald Maintains Overweight on DBV Technologies, Raises Price Target to $48 Cantor Fitzgerald analyst Kristen Kluska maintains DBV Technologies (NASDAQ:DBVT) with a Overweight and raises the price target from $42 to $48.
benzinga.com Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing DBV Technologies reports positive Phase 3 data for its VIASKIN Peanut patch in children, supporting a planned U.S. BLA filing in 2026.- benzinga.com Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $45 Citizens analyst Jonathan Wolleben maintains DBV Technologies (NASDAQ:DBVT) with a Market Outperform and raises the price target from $21 to $45.
- benzinga.com Guggenheim Maintains Buy on DBV Technologies, Raises Price Target to $51 Guggenheim analyst Yatin Suneja maintains DBV Technologies (NASDAQ:DBVT) with a Buy and raises the price target from $35 to $51.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Aditxt Shares Are Trading Higher By Around 63%; Here Are 20 Stocks Moving Premarket 
benzinga.com Micron Technology To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Monday 
benzinga.com This SiTime Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday 
benzinga.com Daktronics, Photronics, Dave & Buster's Entertainment, GE Vernova And Other Big Stocks Moving Higher On Wednesday - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session